+ Watch CTIX
on My Watchlist
likely to rise up
Brilacidin is a competitor of Cubist and Durata for use in gram positive infections. FDA is fast tracking antibiotics.
Nothing much to see here. The powers that control Cellceutix's share price like to keep it between 1.5 and 2 as the company wanders along their strange path to nowhere. Kevetrin is now a year and a half into a dose escalation phase I trial. At this rate the phase III trials should be completed by 2030. Prurisol has been revealed to be a prodrug of the antiretroviral abacavir, which appently has hitherto unrecognized miraculous antiinflammatory properties. Despite what we have been assured is the inevitable multibillion dollar revenues from these two candidates, Cellceutix purchased the pipeline of defunct biopharma Polymedix and plans to continue development of the abandoned antibiotic Brilacidin. A phase IIb trial of Brilacidin vs daptomycin in skin infections is now enrolling. The share price will most likely wander back to the 2 range as management utilizes their Aspire ATM to pay themselves for their troubles.
clinical stage, 3 drugs in development: new antibiotic, anti psoriasis, cancer drug.
Swedish boiler room Value of -44 cents :) http://www.gurufocus.com/stock/CTIX
Fully dependent on current FDA trials at Dana Farber Cancer institute in MA.
Pump N Dump scam.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions